NALIRIFOX and Radiation for Pancreatic Cancer
This study is testing a combination of treatments for people with pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer that is locally advanced or borderline resectable (meaning it's close to important blood vessels). Researchers want to see if giving the chemotherapy drug NALIRIFOX along with radiation therapy (AD-XRT) and another chemotherapy drug called capecitabine before surgery is effective. This approach is called total neoadjuvant therapy (TNT). The study will also look at how well this treatment sequence works, if it causes few or mild side effects, and how it affects your quality of life. You may be able to join if you are 18 or older and meet other health criteria.
- Study design
- This study plans to enroll 60 participants. It is an interventional study, meaning participants will receive a specific treatment.
- What's involved
- You would receive NALIRIFOX for 4 months, given on days 1 and 15 of a 4-week cycle. After NALIRIFOX, you would receive AD-XRT and capecitabine for a period of time.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure event-free survival (EFS) for up to 16 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
At a glance
Conditions
NCT05851924
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Alice Wei, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- event-free survival (EFS)up to 16 weeks
events defined as: 1) progression \[local or systemic progression, per RECIST\], 2) recurrence \[recurrent disease following resection\], or 3) death due to any cause